{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:24:40Z","timestamp":1783596280004,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01526-7","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:47:10Z","timestamp":1783594030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal First-Line Immunotherapy for MSI-H\/dMMR Metastatic Colorectal Cancer: Evidence, Gaps, and Clinical Decision-Making"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1526_CR1","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1526_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"1526_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol"},{"key":"1526_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370.","journal-title":"Lancet Oncol"},{"key":"1526_CR6","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014\u201326.","journal-title":"N Engl J Med"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andre","year":"2025","unstructured":"Andre T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395.","journal-title":"Lancet"},{"issue":"suppl 3","key":"1526_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2026.44.2_suppl.14","volume":"44","author":"CMS Rocha Lima","year":"2026","unstructured":"Rocha Lima CMS, Ou F-S, Caron WP, et al. Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab monotherapy versus mFOLFOX6\/bevacizumab\/atezolizumab in the first-line treatment of patients with dMMR\/MSI-H mCRC (NRG-GI004\/SWOG-S1610). J Clin Oncol. 2026;44(suppl 3):14.","journal-title":"J Clin Oncol"},{"key":"1526_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andre","year":"2025","unstructured":"Andre T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277\u201384.","journal-title":"Ann Oncol"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.22.02462","volume":"41","author":"P Vikas","year":"2023","unstructured":"Vikas P, Messersmith H, Compton C, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol. 2023;41:1943\u20138.","journal-title":"J Clin Oncol"},{"key":"1526_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","volume":"5","author":"R Cohen","year":"2019","unstructured":"Cohen R, Hain E, Buhard O, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 2019;5:551\u20135.","journal-title":"JAMA Oncol"},{"key":"1526_CR12","doi-asserted-by":"crossref","unstructured":"Le DT, Diaz LA Jr, Kim TW, et al. Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023;186:185\u201395.","DOI":"10.1016\/j.ejca.2023.02.016"},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161\u201370.","journal-title":"J Clin Oncol"},{"key":"1526_CR14","doi-asserted-by":"crossref","first-page":"103584","DOI":"10.1016\/j.esmoop.2023.102204","volume":"9","author":"F Pietrantonio","year":"2024","unstructured":"Pietrantonio F, Morano F, Lonardi S, Cremolini C. Systemic treatment of mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer\u2014single versus double checkpoint inhibition. ESMO Open. 2024;9:103584.","journal-title":"ESMO Open"},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"1526_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"1526_CR17","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.esmoop.2023.101622","volume":"8","author":"E Cauchin","year":"2023","unstructured":"Cauchin E, Cohen R, Vernerey D, et al. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study. ESMO Open. 2023;8:101622.","journal-title":"ESMO Open"},{"key":"1526_CR18","first-page":"102887","volume":"133","author":"L Cantini","year":"2026","unstructured":"Cantini L, Tabb\u00f2 F, Mentrasti G, et al. Exploring resistance to immune checkpoint inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer. Cancer Treat Rev. 2026;133:102887.","journal-title":"Cancer Treat Rev"},{"key":"1526_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2022.05.044","volume":"172","author":"G Mazzoli","year":"2022","unstructured":"Mazzoli G, Cohen R, Lonardi S, et al. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR\/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022;172:171\u201381.","journal-title":"Eur J Cancer"},{"key":"1526_CR20","first-page":"115289","volume":"218","author":"R Cohen","year":"2025","unstructured":"Cohen R, Lefebvre C, De La Fouchardiere C, et al. Patterns of progressive disease in patients with MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors: the ImmunoMSI cohort. Eur J Cancer. 2025;218:115289.","journal-title":"Eur J Cancer"},{"key":"1526_CR21","doi-asserted-by":"publisher","first-page":"115645","DOI":"10.1016\/j.ejca.2025.115645","volume":"227","author":"C Gallois","year":"2025","unstructured":"Gallois C, Ambrosini M, Lonardi S, et al. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2025;227:115645.","journal-title":"Eur J Cancer"},{"issue":"suppl 16","key":"1526_CR22","doi-asserted-by":"publisher","first-page":"TPS3634","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3634","volume":"40","author":"S Kopetz","year":"2022","unstructured":"Kopetz S, Elez E, Tabernero J, et al. SEAMARK: randomized phase 2 study of pembrolizumab\u2009+\u2009encorafenib\u2009+\u2009cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and MSI-H\/dMMR metastatic colorectal cancer. J Clin Oncol. 2022;40(suppl 16):TPS3634.","journal-title":"J Clin Oncol"},{"key":"1526_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31:901\u20138.","journal-title":"Nat Med"},{"key":"1526_CR24","unstructured":"ESMO Living guideline. metastatic colorectal cancer: first-line therapy for RAS-mut, BRAF-mut, or dMMR\/MSI-H disease. European Society for Medical Oncology. Updated 2025. Accessed April 2, 2026."},{"key":"1526_CR25","unstructured":"ClinicalTrials.gov. MK-1308A-008: pembrolizumab plus quavonlimab vs pembrolizumab for first-line dMMR\/MSI-H mCRC. NCT04895722. Accessed April 2, 2026."},{"key":"1526_CR26","unstructured":"Sinicrope FA, Ou F-S, Arnold D et al. ATOMIC: atezolizumab plus FOLFOX as adjuvant therapy for stage III dMMR colon cancer. J Clin Oncol. 2025;43(suppl 16)[abstract LBA3500]."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01526-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:47:12Z","timestamp":1783594032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01526-7","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}